Long-term safety and efficacy of long-acting pasireotide in acromegaly.

Amit AkirovAlexander GorshteinIdit DotanNariman Saba KhazenYulia PaukerMichal GershinskyIlan Shimon

Published in: Endocrine (2021)

The results support the long-term efficacy and safety of pasireotide LAR for acromegaly and support the potential delayed effect of treatment on IGF-1 normalization.

Keyphrases

growth hormone
risk assessment
cell proliferation
pi k akt
signaling pathway